# Study to IDEntify Patients With Advanced/Metastatic Non Small Cell Lung Cancer (NSCLC) and ALK and ROS1 Translocation and to Establish Their Therapeutic Management (IDEALK&ROS)

> **NCT02679170** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 692 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Crizotinib

## Key facts

- **NCT ID:** NCT02679170
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-29
- **Primary completion:** 2022-05-04
- **Final completion:** 2022-05-04
- **Target enrollment:** 692 (ACTUAL)
- **Last updated:** 2024-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02679170

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02679170, "Study to IDEntify Patients With Advanced/Metastatic Non Small Cell Lung Cancer (NSCLC) and ALK and ROS1 Translocation and to Establish Their Therapeutic Management (IDEALK&ROS)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02679170. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*